AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17964402 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 185
Study 17964402 — intervention group
Group type: COMPARATOR
Intervention: No ocular hypotensive agent (control group)
Number of subjects: 185
Study 16547381 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) 0.2‐0.2‐0.2 mg/kg
Number of subjects: 35
Study 16547381 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IBU) 10‐5‐5 mg/kg
Number of subjects: 35
Study 16547381 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IBU)
Number of subjects: 35
Study 16547381 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO)
Number of subjects: 35
Study 16547381 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) with hydrocortisone
Number of subjects: 35
Study 12133653 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 203
Study 12133653 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 203
Study 10875825 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5499
Study 9359536 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg 3 times daily)
Number of subjects: 92
Study 9359536 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study 9359536 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 92
Study 8201912 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren sustained release, 100 mg once a day
Number of subjects: 20
Study 8201912 — intervention group
Group type: COMPARATOR
Intervention: Nodo regular formulation, 200 mg once a day
Number of subjects: 20
Study 3018564 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml of intramuscular iodized oil
Number of subjects: 51
Study 3018564 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 51
Study 29235557 — intervention group
Group type: COMPARATOR
Intervention: Fetal-neonatal ID (n=253)
Number of subjects: 1194
Study 29235557 — intervention group
Group type: COMPARATOR
Intervention: Infancy ID (n=288)
Number of subjects: 1194
Study 29235557 — intervention group
Group type: COMPARATOR
Intervention: Fetal-neonatal and infancy ID (n=256)
Number of subjects: 1194
Study 29235557 — intervention group
Group type: COMPARATOR
Intervention: More severe ID in late pregnancy
Number of subjects: 1194
Study 29235557 — intervention group
Group type: COMPARATOR
Intervention: More severe ID in infancy
Number of subjects: 1194
Study 27783129 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of care (frequent contact with mental health services)
Number of subjects: 323
Study 27783129 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in care coordinator
Number of subjects: 323
Study 27783129 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical correspondence copied to patients
Number of subjects: 323
Study 24800313 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, exposure-based intervention
Number of subjects: 40
Study 24800313 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study 23103835 — intervention group
Group type: EXPERIMENTAL
Intervention: Online unguided self-help intervention consisting of 6 modules based on cognitive behavioral techniques.
Number of subjects: 236
Study 23103835 — intervention group
Group type: COMPARATOR
Intervention: Waitlist, information-only control group.
Number of subjects: 236
Study 23103835 — intervention group
Group type: EXPERIMENTAL
Intervention: Online unguided self-help intervention.
Number of subjects: 236
Study 20426866 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Cognitive Stimulation Therapy (CST) for 24 weeks after initial CST for 7 weeks
Number of subjects: 230
Study 20426866 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Stimulation Therapy (CST) for 7 weeks followed by treatment as usual for 24 weeks
Number of subjects: 230
Study 18617301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg twice daily for eGFR 30 to 60 mL/min/1.73 m² or once daily for eGFR 10 to 29 mL/min/1.73 m²)
Number of subjects: 85
Study 18617301 — intervention group
Group type: COMPARATOR
Intervention: Control (Losartan only)
Number of subjects: 85
Study 18617301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (in second stage for both groups)
Number of subjects: 85
Study 15845706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia (Paco(2) 27‐34 mm Hg)
Number of subjects: 12
Study 15845706 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (Paco(2) 38‐43 mm Hg)
Number of subjects: 12
Study 15845706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia
Number of subjects: 12
Study 11921456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI) 300 mg b.i.d. for 24 weeks
Number of subjects: 520
Study 11921456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 10209810 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate adjustment in group randomized trials
Number of subjects: 4
Study 10209810 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking communities according to covariates
Number of subjects: 4
Study 10209810 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate adjustment
Number of subjects: 4
Study 10209810 — intervention group
Group type: EXPERIMENTAL
Intervention: Design of group randomized trials
Number of subjects: 4
Study 8949327 — intervention group
Group type: EXPERIMENTAL
Intervention: Whispered voice test
Number of subjects: 62
Study 8949327 — intervention group
Group type: COMPARATOR
Intervention: Four simple tests for screening for hearing loss
Number of subjects: 62
Study 1741572 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 98
Study 1741572 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytherapy
Number of subjects: 98
Study 1741572 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 98
Study 1741572 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 98
Study 1741572 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 1741572 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital, Carbamazepine, Polytherapy
Number of subjects: 98
Study 1741572 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium, Parathyroid hormone, Osteocalcine
Number of subjects: 98
Study 1741572 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment duration over 3 years
Number of subjects: 98
Study 30920874 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injected on the buccal aspect of supporting teeth
Number of subjects: 18
Study 30920874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP treatment)
Number of subjects: 18
Study 30920874 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP group
Number of subjects: 18
Study 28928319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ask, Brief, Cessation support (ABC) package
Number of subjects: 156
Study 28928319 — intervention group
Group type: COMPARATOR
Intervention: Existing standard of care
Number of subjects: 156
Study 26061140 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-neurturin injected bilaterally into the substantia nigra (2.0 × 10(11) vector genomes) and putamen (1.0 × 10(12) vector genomes)
Number of subjects: 51
Study 26061140 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 51
Study 23490060 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 3405
Study 23490060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3405
Study 21098317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric gluconate 187.5 mg IV every 3 weeks
Number of subjects: 502
Study 21098317 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral daily ferrous sulfate 325 mg
Number of subjects: 502
Study 21098317 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 502
Study 21098317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric gluconate IV
Number of subjects: 502
Study 19675481 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Water Therapy (C(T)WT)
Number of subjects: 10
Study 19675481 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (ACT)
Number of subjects: 10
Study 19675481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 10
Study 19675481 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery
Number of subjects: 10
Study 17376239 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal occlusion
Number of subjects: 26
Study 17376239 — intervention group
Group type: COMPARATOR
Intervention: Distal occlusion
Number of subjects: 26
Study 17376239 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal method
Number of subjects: 26
Study 17376239 — intervention group
Group type: COMPARATOR
Intervention: Distal method
Number of subjects: 26
Study 15017207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sextant biopsies recommended when total PSA was 3 ng/ml or greater at screening rounds 1 and 2, and 2.54 ng/ml or greater at subsequent screening rounds.
Number of subjects: 10000
Study 15017207 — intervention group
Group type: EXPERIMENTAL
Intervention: Total core cancer length of less than 3 mm.
Number of subjects: 10000
Study 15017207 — intervention group
Group type: EXPERIMENTAL
Intervention: Total core cancer length greater than 10 mm.
Number of subjects: 10000
Study 11249885 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stent implantation (DS+)
Number of subjects: 338
Study 11249885 — intervention group
Group type: COMPARATOR
Intervention: Standard stent implantation with balloon predilatation (DS-)
Number of subjects: 338
Study 9487256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate treatment
Number of subjects: 7977
Study 9487256 — intervention group
Group type: COMPARATOR
Intervention: Control group (osteoporosis patients not taking etidronate)
Number of subjects: 7977
Study 7961544 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antidepressants (SSRIs, venlafaxine, bupropion)
Number of subjects: 0
Study 7961544 — intervention group
Group type: COMPARATOR
Intervention: Older tricyclic antidepressants
Number of subjects: 0
Study 2665146 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach
Number of subjects: 0
Study 2665146 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 0
Study 1184167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose
Number of subjects: 60
Study 1184167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% fructose
Number of subjects: 60
Study 1184167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% xylitol
Number of subjects: 60
Study 1184167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% xylitol-glucose-fructose
Number of subjects: 60
Study 1184167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sorbitol
Number of subjects: 60
Study 31009695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy targeting an SpO2 of 90–94% (intervention)
Number of subjects: 1416
Study 31009695 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy targeting an SpO2 of 98–100% (control)
Number of subjects: 1416
Study 29325319 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose spectral CT based on GSI Assist with 50% ASIR (group A)
Number of subjects: 82
Study 29325319 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT with 120 kVp and 30% ASIR (group B)
Number of subjects: 82
Study 29325319 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose spectral CT (group A)
Number of subjects: 82
Study 25410205 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of Peru-15 pCTB vaccine at dosages of 1 ×10(7), 1 ×10(8), 1 ×10(9), and 1 ×10(10) CFU
Number of subjects: 60
Study 25410205 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of Peru-15 pCTB vaccine
Number of subjects: 60
Study 25410205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (buffer alone)
Number of subjects: 60
Study 23539756 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 0
Study 23539756 — intervention group
Group type: COMPARATOR
Intervention: Late parenteral nutrition
Number of subjects: 0
Study 21181601 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative photographic portrayals of an obese person
Number of subjects: 188
Study 21181601 — intervention group
Group type: COMPARATOR
Intervention: Positive photographic portrayals of an obese person
Number of subjects: 188
Study 21181601 — intervention group
Group type: COMPARATOR
Intervention: No photograph
Number of subjects: 188
Study 18955454 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² every 3 weeks plus lapatinib 1,500 mg/d
Number of subjects: 579
Study 18955454 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 579
Study 16939990 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐BDP
Number of subjects: 22
Study 16939990 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone DPI
Number of subjects: 22
Study 14503779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents with medical and social factors leading to admission
Number of subjects: 106
Study 14503779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents assessed for malnutrition and health conditions
Number of subjects: 106
Study 14503779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents with mental health assessments
Number of subjects: 106
Study 14503779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents with chronic conditions
Number of subjects: 106
Study 14503779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents assessed for cognitive impairment
Number of subjects: 106
Study 14503779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents assessed for functional abilities
Number of subjects: 106
Study 10758783 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolon‐ratiopharm 8 mg tablets (test preparation)
Number of subjects: 16
Study 10758783 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation 8 mg tablets (control)
Number of subjects: 16
Study 8824106 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (1200 mg/day)
Number of subjects: 81
Study 8824106 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin (20 mg/day)
Number of subjects: 81
Study 1358133 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 30
Study 1358133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3976757 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate, 250 mg by intramuscular injection once a week
Number of subjects: 80
Study 3976757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27726108 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching session combining visual aids and practical exercises
Number of subjects: 0
Study 27726108 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 27474857 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention condition
Number of subjects: 50
Study 27474857 — intervention group
Group type: COMPARATOR
Intervention: Control instruction condition
Number of subjects: 50
Study 24352580 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction group (n=86)
Number of subjects: 349
Study 24352580 — intervention group
Group type: COMPARATOR
Intervention: Non-extraction group (n=263)
Number of subjects: 349
Study 22622851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal combination therapy including 500 mg metronidazole and 100 mg miconazole nitrate two times a day for 7 days
Number of subjects: 192
Study 22622851 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative vaginal therapy)
Number of subjects: 192
Study 20547012 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional balance proportion (DBP) change scores posttreatment-pretreatment
Number of subjects: 191
Study 20547012 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional balance proportion (DBP) change scores
Number of subjects: 191
Study 18230792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 16
Study 15611838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia transversalis repair (FTR)
Number of subjects: 180
Study 15611838 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein mesh repair
Number of subjects: 180
Study 15611838 — intervention group
Group type: COMPARATOR
Intervention: Preperitoneal mesh repair
Number of subjects: 180
Study 14569243 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate recovery 1 minute after exercise
Number of subjects: 304
Study 14569243 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate recovery
Number of subjects: 304
Study 10619824 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (500 microg twice daily)
Number of subjects: 15
Study 10619824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (in vitro studies)
Number of subjects: 15
Study 8858403 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 12
Study 8858403 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 12
Study 1495520 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6090
Study 6712851 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.006 mg kg‐1 5 min before induction of anaesthesia
Number of subjects: 2
Study 6712851 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 2
Study 30595056 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session smoking intervention based on the theory of planned behavior and life skills training.
Number of subjects: 106
Study 30595056 — intervention group
Group type: COMPARATOR
Intervention: Control group (101 students).
Number of subjects: 106
Study 27836715 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisation Theater (IT) program, 60 min sessions weekly for 12 weeks
Number of subjects: 22
Study 27836715 — intervention group
Group type: COMPARATOR
Intervention: Control group (CS)
Number of subjects: 22
Study 26581787 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (once- or twice-weekly)
Number of subjects: 155
Study 26581787 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training
Number of subjects: 155
Study 26581787 — intervention group
Group type: COMPARATOR
Intervention: Balance-and-toning (twice-weekly)
Number of subjects: 155
Study 23886521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1mg/mL
Number of subjects: 27
Study 23886521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 10mg/mL
Number of subjects: 27
Study 23886521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 22044855 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral (ARV) regimens/strategies
Number of subjects: 4630
Study 19382010 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR) 12.5-62.5 mg/day
Number of subjects: 112
Study 19382010 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR)
Number of subjects: 112
Study 19382010 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 112
Study 17005075 — intervention group
Group type: EXPERIMENTAL
Intervention: Quyu Xiaoban Capsule (QYXBC) for 10 months
Number of subjects: 42
Study 17005075 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 42
Study 12725259 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin in addition to antisnake venom (ASV)
Number of subjects: 122
Study 12725259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 122
Study 11382658 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A + Zinc
Number of subjects: 202
Study 11382658 — intervention group
Group type: COMPARATOR
Intervention: Zinc alone
Number of subjects: 202
Study 11382658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 11382658 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A alone (Placebo for Zinc)
Number of subjects: 202
Study 11382658 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene + Zinc
Number of subjects: 202
Study 11382658 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene alone
Number of subjects: 202
Study 9542610 — intervention group
Group type: COMPARATOR
Intervention: Mite-allergic patients
Number of subjects: 75
Study 9542610 — intervention group
Group type: COMPARATOR
Intervention: Grass pollen-allergic patients (out of season)
Number of subjects: 75
Study 9542610 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen-allergic patients (intraseasonal)
Number of subjects: 75
Study 9542610 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of intraseasonal grass pollen-allergic patients to mite-allergic patients
Number of subjects: 75
Study 7909642 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (Group S)
Number of subjects: 24
Study 7909642 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (Group E)
Number of subjects: 24
Study 7909642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal and epidural anaesthesia (Group SE)
Number of subjects: 24
Study 7909642 — intervention group
Group type: COMPARATOR
Intervention: Prehydration with balanced electrolyte solution
Number of subjects: 24
Study 7909642 — intervention group
Group type: COMPARATOR
Intervention: Apgar score and acid-base status of umbilical artery and vein
Number of subjects: 24
Study 2445540 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 86
Study 2445540 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 86
Study 29924310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyvek® Classic Plus
Number of subjects: 42
Study 29924310 — intervention group
Group type: EXPERIMENTAL
Intervention: HF Estufa polyamide (Brisa®)
Number of subjects: 42